启迪药业(000590) - 2015 Q3 - 季度财报

Financial Performance - Revenue for the reporting period reached CNY 65,547,074.43, a year-on-year increase of 30.41%[6] - Net profit attributable to shareholders was CNY 20,196,231.12, reflecting a significant increase of 2,226.56% year-to-date[6] - The net profit excluding non-recurring gains and losses was CNY 20,193,813.10, up 648.75% compared to the same period last year[6] - Basic earnings per share were CNY 0.0904, representing a year-on-year increase of 2,211.48%[6] - The company's total operating revenue for the current period reached CNY 225,793,780.28, a significant increase from CNY 144,231,333.68 in the previous period, representing a growth of approximately 56.7%[42] - The net profit for the current period was CNY 31,498,822.60, compared to CNY 1,353,881.86 in the previous period, indicating a substantial increase of about 2,228.5%[43] - The total comprehensive income for the current period was CNY 31,335,959.35, compared to CNY 1,754,381.86 in the previous period, marking an increase of about 1,684.5%[44] - Operating profit for the current period was CNY 34,928,329.76, a significant rise from CNY 5,354,365.63 in the previous period, representing an increase of approximately 552.5%[43] Assets and Liabilities - Total assets increased by 5.64% to CNY 619,933,693.13 compared to the end of the previous year[6] - The total assets reached 619,933,693.13 yuan, up from 586,820,654.17 yuan at the beginning of the period[27] - Total liabilities stood at CNY 202,142,677.44, up from CNY 145,843,874.45 at the start of the period[32] - The company's equity attributable to shareholders rose to CNY 170,762,381.18, compared to CNY 167,641,440.47 previously[32] - The total liabilities and equity combined reached CNY 372,905,058.62, reflecting the company's financial position[32] Cash Flow - The company reported a net cash flow from operating activities of CNY 12,658,966.49 year-to-date[6] - Cash flow from operating activities netted 69,255,696.11 yuan, reflecting an increase due to higher cash received from sales of goods and services[14] - The cash flow from operating activities generated a net amount of ¥12,658,966.49, recovering from a negative cash flow of ¥56,596,729.62 in the previous period[51] - The net cash flow from financing activities was ¥3,738,316.65, down from ¥49,560,032.06 in the previous period, indicating a reduction in financing activities[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,506[10] - The largest shareholder, Tsinghua Unigroup, held 18.61% of the shares, amounting to 41,561,800 shares[10] - The second-largest shareholder, the Hunan Provincial Government, held 16.99% of the shares, totaling 37,935,831 shares, with 18,100,000 shares pledged[10] Operational Highlights - Main business revenue increased by 81,562,446.60 yuan, a growth of 56.55%, attributed to higher sales of traditional Chinese medicine[14] - Operating costs amounted to CNY 45,520,418.77, with the cost of goods sold at CNY 27,565,405.10, up from CNY 21,866,142.05 in the prior period[35] - The company reported sales expenses of CNY 35,535,386.54 for the current period, compared to CNY 25,935,794.83 in the previous period, reflecting an increase of about 37.1%[42] Investment and Financing Activities - The company plans to issue new shares through a non-public offering, pending approval from the shareholders' meeting and the China Securities Regulatory Commission[16] - The company reported a significant decrease in cash flow from financing activities, down by 45,821,715.41 yuan, a decline of 92.46% compared to the previous year[15] Other Financial Metrics - The weighted average return on equity was 9.81%, compared to 15.77% at the end of the previous year[6] - Other comprehensive income after tax showed a loss of CNY 1,264,238.25, contrasting with a gain of CNY 193,500.00 in the prior period[35] - The company experienced a decrease in other comprehensive income, with a net amount of CNY -162,863.25 for the current period, compared to CNY 400,500.00 in the previous period[43]